The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Evaluation & Treatment of Systemic Sclerosis-ILD in the New Decade

Evaluation & Treatment of Systemic Sclerosis-ILD in the New Decade

December 17, 2020 • By Thomas R. Collins

  • Tweet
  • Email
Print-Friendly Version / Save PDF

New Therapies
With last year’s approval of the tyrosine kinase-inhibitor nintedanib and trial results of the antifibrotic agent pirfenidone awaited, it is an exciting time for the treatment of SSc-ILD, said Richard Silver, MD, professor of medicine and pediatrics at the Medical University of South Carolina, Charleston.

You Might Also Like
  • FDA Approves Tocilizumab to Treat Systemic Sclerosis-Associated ILD
  • Treatment Tips for Pulmonary Arterial Hypertension & ILD
  • From the Expert: New Advances in Treatment of Systemic Scleroderma
Explore This Issue
January 2021
Also By This Author
  • EULAR 2015: Problems with Biomarkers

“I think we’re on the cusp of a new era of treatment for this very serious complication of scleroderma,” Dr. Silver said.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The recent progress and the promise for even more treatments are a welcome evolution for a sector of the rheumatology field that until only a few years ago had cyclophosphamide, with its long-term safety concerns, as its main option.3

Mycophenolate mofetil, with the publication of the Scleroderma Lung Study II, became another option for patients, as they were able to remain on the drug longer than they could stay on cyclophosphamide, Dr. Silver said.4 And last year, the U.S. Food & Drug Administration approved nintedanib, which showed statistically significant improvement in slowing the rate of FVC over a year, compared to placebo, whether or not it was combined with mycophenolate mofetil.5

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

In the Scleroderma Lung Study III trial, researchers are evaluating the efficacy of the up-front combination of mycophenolate mofetil plus pirfenidone, compared to mycophenolate mofetil plus placebo.6 Pirfenidone is already approved for idiopathic pulmonary fibrosis.

Rituximab and tocilizumab remain possible options for SSc-ILD patients in the future, but so far the evidence is inconclusive—for instance, in the faSScinate trial of tocilizumab, the primary endpoint of change in skin score wasn’t met, but the data suggested that it tended to stabilize lung function in patients with ILD, Dr. Silver said.7

“We need additional trials for both of these agents,” Dr. Silver concluded.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Thomas R. Collins is a freelance writer living in South Florida.

References

  1. Hoffmann-Vold AM, Allanore Y, Alves M, et al. Progressive  interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database. Ann Rheum Dis. 2020 Sep 28;annrheumdis-2020-217455. [Epub ahead of print.]
  2. Wu W, Jordan S, Becker MO, et al. Prediction  of progression of interstitial lung disease in patients with systemic sclerosis: The SPAR model . Ann Rheum Dis. 2018 Sep;77(9):1326­–1332.
  3. Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide  versus placebo in scleroderma lung disease. N Engl J Med. 2006 Jun 22;354(25):2655–2666.
  4. Tashkin DP, Roth MD, Clements PJ, et al. Mycophenolate  mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): A randomised controlled, double-blind, parallel group trial. Lancet Respir Med. 2016 Sep;4(9):708–719.
  5. Distler O, Highland KB, Gahlemann M, et al. Nintedanib  for systemic sclerosis-associated interstitial lung disease. N Engl J Med. 2019 Jun 27;380(26):2518–2528.
  6. University of California, Los Angeles and Genentech Inc. Scleroderma  lung study III—Combining pirfenidone with mycophenolate (SLSIII)(NCT03221257). ClinicalTrials.gov. 2017 July 18.
  7. Khanna D, Denton CP, Lin CJF, et al. Safety  and efficacy of subcutaneous tocilizumab in systemic sclerosis: Results from the open-label period of a phase II randomised controlled trial (faSScinate). Ann Rheum Dis. 2018 Feb;77(2):212–220.

Pages: 1 2 3 | Single Page

Filed Under: ACR Convergence, Conditions, Meeting Reports Tagged With: ACR Convergence 2020, ILD, interstitial lung disease (ILD), Systemic sclerosisIssue: January 2021

You Might Also Like:
  • FDA Approves Tocilizumab to Treat Systemic Sclerosis-Associated ILD
  • Treatment Tips for Pulmonary Arterial Hypertension & ILD
  • From the Expert: New Advances in Treatment of Systemic Scleroderma
  • 2013 ACR/ARHP Annual Meeting: Strides Made in Understanding Systemic Sclerosis

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.